The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells ...
Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, manufacturing complexity, and limited effectiveness against solid tumors.